ID: ALA5273009

Max Phase: Preclinical

Molecular Formula: C41H58O13

Molecular Weight: 758.90

Associated Items:

Representations

Canonical SMILES:  CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@H](O[C@H]2CC[C@]34C[C@]35CC(=O)[C@]3(C)[C@H]6[C@H](C)C[C@]7(OC(O)[C@@]8(C)O[C@@H]78)O[C@H]6C[C@@]3(C)[C@@H]5CC[C@H]4C2(C)C)OC[C@H]1OC(C)=O

Standard InChI:  InChI=1S/C41H58O13/c1-19-14-41(33-38(9,53-33)34(46)54-41)52-23-15-36(7)26-11-10-25-35(5,6)28(12-13-39(25)18-40(26,39)16-27(45)37(36,8)29(19)23)51-32-31(50-22(4)44)30(49-21(3)43)24(17-47-32)48-20(2)42/h19,23-26,28-34,46H,10-18H2,1-9H3/t19-,23+,24-,25+,26+,28+,29+,30+,31-,32+,33-,34?,36+,37-,38+,39-,40+,41-/m1/s1

Standard InChI Key:  NVEQPFOIYVPQSC-NYFOCMNHSA-N

Associated Targets(Human)

HCC1806 544 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MDA-MB-231 73002 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 758.90Molecular Weight (Monoisotopic): 758.3877AlogP: 4.38#Rotatable Bonds: 5
Polar Surface Area: 165.65Molecular Species: NEUTRALHBA: 13HBD: 1
#RO5 Violations: 2HBA (Lipinski): 13HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.10CX Basic pKa: CX LogP: 4.19CX LogD: 4.19
Aromatic Rings: 0Heavy Atoms: 54QED Weighted: 0.18Np Likeness Score: 2.81

References

1. Zhang H, Chen Y, Huang S, Xiao WW, Qiu MH, Shao LD, Chen CH, Li D..  (2023)  Development of actein derivatives as potent anti-triple negative breast cancer agents.,  89  [PMID:37121522] [10.1016/j.bmcl.2023.129307]

Source